查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1747777

高階細胞組學的全球市場

High End Cellomics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 212 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球高階細胞組學市場規模將達到 70 億美元

全球高階細胞組學市場規模預計在2024年為46億美元，預計2030年將達到70億美元，2024年至2030年的複合年成長率為7.2%。作為報告分析的細分市場之一，儀器市場預計複合年成長率為6.2%，到分析期結束時規模將達到38億美元。試劑和耗材市場預計在分析期間內複合年成長率為8.3%。

美國市場規模預估為 12 億美元，中國市場預期複合年成長率為 7.1%

美國高階細胞組學市場規模預計在2024年達到12億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到11億美元，在2024-2030年的分析期間內，複合年成長率為7.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為6.5%和6.2%。在歐洲，預計德國市場的複合年成長率約為6.0%。

全球高階細胞組學市場—主要趨勢與促進因素摘要

是什麼推動了高階CELLOMICS在精準研究中的快速崛起？

高階CELLOMICS在單細胞分析、活細胞成像和高內涵篩檢方面提供了前所未有的能力，並已成為生物醫學研究發展的關鍵領域。該領域融合了先進的生物成像、機器學習演算法和微流體技術，以在超精細層面上解讀細胞行為。改變該領域的一個核心趨勢是從傳統的基於群體的分析轉向單細胞方法，這種方法消除了細胞異質性，並產生了更準確、更具有臨床相關性的見解。高通量顯微鏡和即時人工智慧分析的結合，可以捕捉隨時間推移的動態細胞事件，而不僅僅是靜態簡介，從而使研究人員能夠高保真地追蹤訊號傳遞、細胞週期轉變和凋亡過程。

多體學技術的平行發展進一步拓寬了細胞組學的應用範圍。將單一細胞的基因組、轉錄組、蛋白質組和代謝組學特徵關聯起來的能力，已使該領域超越了單純的可視化。如今，高階CELLOMICS學平台對於在單細胞解析度下理解腫瘤微環境、免疫細胞功能和幹細胞分化至關重要。因此，製藥公司正在大力投資用於高內涵表現型篩檢的CELLOMICS工具，尤其是在腫瘤學、免疫療法和神經退化疾病治療領域。其效用正在擴展，涵蓋治療方法發現、毒理學分析和基於細胞的檢測，進一步鞏固了細胞組學作為下一代精準醫療關鍵支柱的地位。

影像、人工智慧和流體學方面的創新如何重塑CELLOMICS套件？

高階CELLOMICS市場轉型的核心是技術的融合。螢光和超高解析度顯微鏡的創新，例如受激發光衰減顯微鏡 (STED) 和構造化照明顯微鏡 (SIM)，顯著提高了亞細胞研究所需的解析度和對比度。結合活細胞成像功能，研究人員現在可以在最小的光毒性下觀察細胞內相互作用和表現型隨時間的變化。此外，光學元件的微型化和自動化孔板處理系統的整合，使得在單次實驗中跨越數百甚至數千個孔的可擴展成像工作流程成為可能。

人工智慧已成為高階CELLOMICS的重要增強器。機器學習演算法擴大用於自動影像分割、特徵提取和預測表現型分析。基於海量細胞影像庫進行訓練的深度學習平台如今可以即時分類細微的形態變化，從而有助於更準確地進行藥物療效測試。此外，人工智慧支援的異常檢測和軌跡追蹤正在將CELLOMICS從靜態分析工具提升為動態決策系統。微流體系統的加入也增強了CELLOMICS平台的分析能力，使其能夠實現微尺度上的精確細胞分選、環境控制和試劑輸送。

高階細胞組學有哪些應用？

高階細胞組學的應用領域正在迅速多樣化，尤其是在藥物研發、毒理學、免疫學和再生醫學領域。在藥物研發中，CELLOMICS在化合物篩檢中發揮關鍵作用，因為它能夠在細胞和亞細胞層面評估藥物反應，而無需僅依賴生物標記。這對於在藥物開發平臺早期識別脫靶效應和最佳化給藥方法至關重要。癌症研究是CELLOMICS的關鍵領域，它正在改變科學家分析異質性腫瘤樣本、評估免疫細胞浸潤和預測抗治療性模式的方式。

在免疫學領域，CELLOMICS可以對T細胞、B細胞和呈現抗原細胞進行功能分析，而這在傳統方法中是無法實現的。這對於疫苗開發和免疫腫瘤學具有重要意義，因為精細的免疫細胞監測可以指南設計和療效評估。同樣，幹細胞生物學也受益於高階CELLOMICS，實現了分化途徑、譜系追蹤和隨時間推移的表觀遺傳學變化監測。臨床實驗室和合約研究組織（CRO）也在採用CELLOMICS工具進行患者分層和生物標記檢驗，而大規模分析細胞群的能力則支持個性化治療計劃和病情進展監測。這種在臨床前和轉化環境中日益成長的應用凸顯了高階CELLOMICS在現代生物科學中應用範圍的不斷擴大。

高階CELLOMICS市場的成長受到多種因素的推動…

成長的驅動力源自於高內涵分析平台日益複雜化和需求的提升，尤其是在製藥和生技產業。其中，關鍵促進因素是對預測毒理學和表現型篩檢系統日益成長的需求，而細胞組學與傳統方法相比，擁有更高的通量和準確性。此外，不斷擴展的免疫療法和細胞療法研發管線需要高解析度、動態影像工具來了解單細胞層級的免疫反應。多重檢測和高通量篩檢的普及，也推動了對整合像、數據分析和自動化於一體的整合解決方案的需求。

學術和轉化研究中心也正在投資高階CELLOMICS學平台，以提高其闡明複雜疾病機制和檢驗治療標靶的能力。患者來源的類器官和3D細胞培養系統的重要性日益成長，這進一步激發了市場對能夠成像和分析非層級構造的平台的興趣。此外，政府和私人資金正在推動先進的CELLOMICS系統在生命科學研究中的廣泛應用，尤其是在腫瘤學、神經科學和罕見疾病等領域。最後，光學硬體、計算生物學和檢測微型化的不斷進步，使得高階CELLOMICS工具更易於獲取、可擴展，並適用於更廣泛的科學探索。

部分

產品類型（儀器、試劑和耗材、軟體和服務）、應用（藥物研發、癌症研究、神經科學、幹細胞研究和再生醫學、個人化醫療、其他應用）、技術（顯微鏡、流式細胞技術、單細胞基因組學、質譜、次世代定序儀、其他技術）、最終用途（製藥和生物技術公司、醫院和診斷、實驗室合約組織、其他用途）

受訪企業範例（共34家）

  • 10x Genomics
  • Agilent Technologies
  • BD（Becton, Dickinson）
  • Bio-Rad Laboratories
  • Bio-Techne
  • Bruker Corporation
  • Cellenion
  • Cellomics Technology
  • CYTENA GmbH
  • Danaher Corporation
  • Dolomite Bio
  • GE Healthcare
  • Illumina Inc.
  • Luminex Corporation
  • Merck KGaA
  • Miltenyi Biotec
  • NanoString Technologies
  • PerkinElmer Inc.
  • Sphere Fluidics
  • Thermo Fisher Scientific

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）預測公司競爭定位的變化。這種複雜且多方面的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP35174

Global High End Cellomics Market to Reach US$7.0 Billion by 2030

The global market for High End Cellomics estimated at US$4.6 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 7.1% CAGR

The High End Cellomics market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global High-End Cellomics Market - Key Trends & Drivers Summarized

What Is Driving the Rapid Emergence of High-End Cellomics in Precision Research?

High-end cellomics is emerging as a pivotal discipline in the evolving landscape of biomedical research, offering unprecedented capabilities in single-cell analysis, live-cell imaging, and high-content screening. This field represents the fusion of advanced bioimaging, machine learning algorithms, and microfluidic technologies to decode cellular behavior at an ultra-granular level. A core trend transforming the sector is the shift from traditional population-based assays to single-cell approaches that eliminate cellular heterogeneity and yield more precise, clinically relevant insights. The integration of high-throughput microscopy with real-time AI-enabled analysis has made it possible to capture not just static snapshots but dynamic cellular events over time, allowing researchers to track signaling cascades, cell cycle transitions, and apoptotic processes with high fidelity.

A parallel surge in multi-omics technologies has further enhanced the scope of cellomics. The capacity to correlate genomic, transcriptomic, proteomic, and metabolomic profiles from individual cells has propelled the field beyond mere visualization. High-end cellomics platforms are now essential for understanding tumor microenvironments, immune cell function, and stem cell differentiation at single-cell resolution. As a result, pharmaceutical companies are investing heavily in cellomics tools for high-content phenotypic screening, especially in oncology, immunotherapy, and neurodegenerative drug development. The expanding utility across therapeutic discovery, toxicological profiling, and cell-based assays is reinforcing cellomics as a critical pillar in the next generation of precision medicine.

How Are Innovations in Imaging, AI, and Fluidics Reshaping the Cellomics Toolkit?

Technological convergence lies at the heart of the high-end cellomics market transformation. Innovations in fluorescence and super-resolution microscopy, such as stimulated emission depletion (STED) and structured illumination microscopy (SIM), have substantially improved the resolution and contrast needed for subcellular studies. Coupled with live-cell imaging capabilities, researchers can now observe intracellular interactions and phenotypic changes over time with minimal phototoxicity. This is further supported by the miniaturization of optical components and the integration of automated plate handling systems, enabling scalable imaging workflows across hundreds or thousands of wells in a single experiment.

Artificial intelligence has emerged as an indispensable force multiplier in high-end cellomics. Machine learning algorithms are increasingly used for automated image segmentation, feature extraction, and predictive phenotyping. Deep learning platforms trained on vast libraries of cellular images now allow real-time classification of subtle morphological changes, aiding in more precise drug efficacy testing. Moreover, AI-driven anomaly detection and trajectory tracking have elevated cellomics from a static analysis tool to a dynamic decision-making system. The inclusion of microfluidic systems has also bolstered the analytical capabilities of cellomics platforms by facilitating precise cell sorting, environmental control, and reagent delivery at the microscale, which is particularly vital for longitudinal studies on rare cell populations.

Where Is High-End Cellomics Gaining Ground Across Applications?

The applications of high-end cellomics are rapidly diversifying, particularly within the realms of drug discovery, toxicology, immunology, and regenerative medicine. In pharmaceutical R&D, cellomics plays a key role in compound screening, allowing researchers to assess drug responses at the cellular and subcellular levels without relying on biomarkers alone. This is critical for identifying off-target effects and optimizing dosage regimes early in the drug development pipeline. Cancer research stands out as a dominant domain where cellomics is transforming how scientists profile heterogeneous tumor samples, evaluate immune cell infiltration, and predict therapeutic resistance patterns.

In immunology, cellomics enables functional profiling of T cells, B cells, and antigen-presenting cells in ways not possible through traditional methods. This has profound implications for vaccine development and immune-oncology, where fine-tuned immune cell monitoring can guide both design and efficacy evaluation. Similarly, stem cell biology is benefiting from high-end cellomics by enabling researchers to monitor differentiation pathways, lineage tracing, and epigenetic shifts over time. Clinical laboratories and CROs are also deploying cellomics tools for patient stratification and biomarker validation, where the ability to analyze cell populations at scale supports personalized treatment planning and disease progression monitoring. This growing use across preclinical and translational settings underscores the broadening reach of high-end cellomics in modern biosciences.

The Growth in the High-End Cellomics Market Is Driven by Several Factors…

It is primarily the increasing sophistication and demand for high-content analysis platforms in pharmaceutical and biotechnology industries that is fueling growth. Key among these drivers is the rising need for predictive toxicology and phenotypic screening systems, where cellomics offers superior throughput and accuracy compared to conventional methods. The expansion of immunotherapy and cell therapy pipelines has also necessitated high-resolution, dynamic imaging tools for understanding immune responses at the single-cell level. Furthermore, the proliferation of multiplexed assays and high-throughput screening campaigns is driving demand for integrated solutions that combine imaging, data analytics, and automation.

Academic and translational research centers are also investing in high-end cellomics platforms to enhance their ability to dissect complex disease mechanisms and validate therapeutic targets. The growing importance of patient-derived organoids and 3D cell culture systems has further bolstered market interest in platforms capable of imaging and analyzing non-monolayer structures. Additionally, government and private funding in life sciences research, particularly in areas like oncology, neuroscience, and rare diseases, is supporting the widespread adoption of advanced cellomics systems. Finally, the continuous advancements in optical hardware, computational biology, and assay miniaturization are making high-end cellomics tools more accessible, scalable, and applicable across a wider range of scientific inquiries.

SCOPE OF STUDY:

The report analyzes the High End Cellomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Application (Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine, Other Applications); Technology (Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing, Other Technologies); End-Use (Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • 10x Genomics
  • Agilent Technologies
  • BD (Becton, Dickinson)
  • Bio-Rad Laboratories
  • Bio-Techne
  • Bruker Corporation
  • Cellenion
  • Cellomics Technology
  • CYTENA GmbH
  • Danaher Corporation
  • Dolomite Bio
  • GE Healthcare
  • Illumina Inc.
  • Luminex Corporation
  • Merck KGaA
  • Miltenyi Biotec
  • NanoString Technologies
  • PerkinElmer Inc.
  • Sphere Fluidics
  • Thermo Fisher Scientific

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • High End Cellomics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Content Screening in Drug Discovery Drives Adoption of Advanced Cellomics Platforms
    • Growth in Personalized Medicine and Precision Oncology Spurs Investment in Cell-Based Analytical Technologies
    • Expansion of Cell-Based Assays in Toxicology and Target Validation Fuels Market for High-End Imaging and Quantification Systems
    • Integration of AI and Deep Learning Algorithms Enhances Cellomics Image Analysis Accuracy and Throughput
    • Increased Adoption of 3D Cell Culture and Organoids Boosts Demand for Sophisticated, High-Resolution Cell Imaging Systems
    • Automation and Miniaturization Trends in High-Throughput Screening Support Deployment of Fully Integrated Cellomics Workstations
    • Rising R&D Expenditure by Pharmaceutical and Biotechnology Companies Drives Large-Scale Investment in Cellomics Infrastructure
    • Growing Applications in Stem Cell Research and Regenerative Medicine Expand the Market for Functional Cell Phenotyping Tools
    • Technological Advancements in Fluorescence and Live-Cell Imaging Elevate Performance of Next-Generation Cellomics Platforms
    • Surge in Use of Cellomics in Immuno-Oncology and CAR-T Therapy Research Strengthens Market Expansion
    • Increased Focus on Multi-Parameter Analysis Drives Demand for Multiplexed and High-Content Cellomics Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World High End Cellomics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for High End Cellomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for High End Cellomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Microscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Single-Cell Genomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Single-Cell Genomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Hospitals & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Neuroscience by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Neuroscience by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Stem Cell Research & Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Stem Cell Research & Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • JAPAN
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 58: Japan Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • CHINA
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 66: China Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • EUROPE
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for High End Cellomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for High End Cellomics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • FRANCE
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 84: France Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • GERMANY
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 108: UK Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • High End Cellomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for High End Cellomics by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by Technology - Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for High End Cellomics by Technology - Percentage Breakdown of Value Sales for Microscopy, Flow Cytometry, Single-Cell Genomics, Mass Spectrometry, Next Generation Sequencing and Other Technologies for the Years 2025 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by End-Use - Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for High End Cellomics by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Laboratories, Contract Research Organizations and Other End-Uses for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for High End Cellomics by Application - Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for High End Cellomics by Application - Percentage Breakdown of Value Sales for Drug Discovery, Cancer Research, Neuroscience, Stem Cell Research & Regenerative Medicine, Personalized Medicine and Other Applications for the Years 2025 & 2030

IV. COMPETITION